About HRA Pharma
Data last updated:
HRA Pharma is a company based in Paris (France) founded in 1996 was acquired by Perrigo in September 2021. HRA Pharma has completed 2 acquisitions, including Compeed and Mederma.
- Headquarter Paris, France
- SectorsHealthcare
- EmailLocked
- PhoneLocked
- WebsiteLocked
- SocialLocked
- Annual Revenue$4.93 M (USD)22as on Mar 31, 2022
- Net Profit$30.51 K (USD)29as on Mar 31, 2022
- EBITDANot available
- Latest Funding Round$704.38 K (USD), Grant
Feb 23, 2009
- InvestorsGoldman Sachs
& 4 more
- Employee CountNot available
- Investments & AcquisitionsCompeed
& 1 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of HRA Pharma
Unlock access to complete
Funding Insights of HRA Pharma
Investors in HRA Pharma
HRA Pharma has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, HHS and Perrigo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment banking services are delivered across multiple financial sectors. | Locked | Locked | Locked | |
Astorg is engaged in private equity investment management. | Locked | Locked | Locked | |
Private equity and debt are provided to middle market companies. | Locked | Locked | Locked |
Investor details for HRA Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HRA Pharma
HRA Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Compeed and Mederma.
Investment portfolio details for HRA Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
Compressed plasters are manufactured by Compeed for wound protection. | Locked | Locked | 1986 | Locked | |
Mederma is recognized for skin care products targeting scars. | Locked | Locked | 0 | Locked |
Complete acquisition details for HRA Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - HRA Pharma
Detailed financials for HRA Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hra Pharma Comparisons
Peer comparison for HRA Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HRA Pharma
Detailed competitors of HRA Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hra Pharma
Complete news archive for HRA Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HRA Pharma
HRA Pharma was founded in 1996 and raised its 1st funding round 13 years after it was founded.
HRA Pharma is headquartered in Paris, France.
Annual revenue of HRA Pharma is $4.93M as on Mar 31, 2022.
HRA Pharma is a privately-held European pharmaceutical company that designs products and targets therapeutic gaps in the areas of womens health and endocrinology. It offers reproductive health products, which include Norlevo for emergency contraception; Cicatridine for vaginitis and vaginal injury; Delidose, Divina, and Duova for HRT; GyMiso for cervical ripening; and Mona Lisa, a copper contraceptive intrauterine device, as well as endocrinal products that include Lysodren and Lysosafe for adrenal cancer. The company also provides Bemedrex for asthma; Deprenyl for Parkinsons disease; and information and associated services for healthcare providers and other users. In addition, its development pipeline comprises ellaellaOne, an emergency contraceptive pill; UPA UF, a treatment for uterine fibroids; UPA contraceptive products; Mifedren, a product candidate for a subset of Cushings syndromes caused by ectopic ACTH(1) secretion; and cell-based therapies for muscle regeneration.
HRA Pharma has 5 investors. Key investors include Goldman Sachs, HHS, Perrigo, Astorg, and The Riverside Company.